Jiajun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiajun Li has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Keran Li
Department of Ophthalmology, The Affiliated Eye Hospital of Nanjing Medical University, Nanjing, China
3 shared publications - Ziyi Chen
Department of Ophthalmology, Eye Hospital of Nanjing Medical University, Nanjing 210029, China
2 shared publications - Changgong Lan
Department of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Ethnic Medical University, Baise, 533000, China
1 shared publication - Cong Cao
Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow University, Suzhou, China
1 shared publication - Guangguang Wu
Department of Ophthalmology, Eye Hospital of Nanjing Medical University, Nanjing 210029, China
1 shared publication - Jin Yao
The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6599
Clinical Interchangeability Boundaries of Pentacam AXL WAVE in Preoperative Biometry for Cataract Surgery: An Agreement Study with IOLMaster 700 and Pentacam
Background/Objectives: Accurate preoperative biometry is essential for refractive cataract surgery. Pentacam AXL WAVE is an emerging multimodal platform integrating ocular biometry, anterior segment imaging, and corneal assessment, yet its interchangeability with established devices remains unclear. This study aimed to evaluate the agreement and clinical interchangeability of Pentacam AXL WAVE with IOLMaster 700 and Pentacam. Methods: This retrospective cross-sectional study compared Pentacam AXL WAVE with IOLMaster 700 and Pentacam across 175 eyes of 105 cataract patients. Interdevice agreement was evaluated using intraclass correlation coefficients, concordance correlation coefficients, and Bland–Altman analysis with multiple outlier-handling strategies; generalized estimating equations were applied to identify clinical factors associated with interdevice differences. Results: Pentacam AXL WAVE demonstrated good agreement with IOLMaster 700 and Pentacam for axial length and anterior corneal curvature parameters, but showed weaker agreement for white-to-white diameter, total keratometry, total corneal astigmatic vectors, and several extended anterior segment parameters. Fewer clinical factors explained interdevice differences versus IOLMaster 700, whereas ocular surface or corneal abnormalities, refractive status, and cataract characteristics were associated with greater differences versus Pentacam. Conclusions: These findings indicate that Pentacam AXL WAVE has parameter-specific interchangeability boundaries and can meet some routine biometric needs; however, for eyes requiring high refractive precision or presenting with complex ocular conditions, interpretation should be based on the agreement characteristics of individual parameters.
- 26 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6599
Open AccessClinical Interchangeability Boundaries of Pentacam AXL WAVE in Preoperative Biometry for Cataract Surgery: An Agreement Study with IOLMaster 700 and Pentacam
Background/Objectives: Accurate preoperative biometry is essential for refractive cataract surgery. Pentacam AXL WAVE is an emerging multimodal platform integrating ocular biometry, anterior segment imaging, and corneal assessment, yet its interchangeability with established devices remains unclear. This study aimed to evaluate the agreement and clinical interchangeability of Pentacam AXL WAVE with IOLMaster 700 and Pentacam. Methods: This retrospective cross-sectional study compared Pentacam AXL WAVE with IOLMaster 700 and Pentacam across 175 eyes of 105 cataract patients. Interdevice agreement was evaluated using intraclass correlation coefficients, concordance correlation coefficients, and Bland–Altman analysis with multiple outlier-handling strategies; generalized estimating equations were applied to identify clinical factors associated with interdevice differences. Results: Pentacam AXL WAVE demonstrated good agreement with IOLMaster 700 and Pentacam for axial length and anterior corneal curvature parameters, but showed weaker agreement for white-to-white diameter, total keratometry, total corneal astigmatic vectors, and several extended anterior segment parameters. Fewer clinical factors explained interdevice differences versus IOLMaster 700, whereas ocular surface or corneal abnormalities, refractive status, and cataract characteristics were associated with greater differences versus Pentacam. Conclusions: These findings indicate that Pentacam AXL WAVE has parameter-specific interchangeability boundaries and can meet some routine biometric needs; however, for eyes requiring high refractive precision or presenting with complex ocular conditions, interpretation should be based on the agreement characteristics of individual parameters.
- Open Access
- 12 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11984
When Mitochondria Falter, the Barrier Fails: Mechanisms of Inner Blood-Retinal Barrier (iBRB) Injury and Opportunities for Mitochondria-Targeted Repair
As the central hub of retinal metabolism, mitochondria are vital for sustaining the integrity of the inner blood-retinal barrier (iBRB), which is fundamental to retinal homeostasis. Mitochondrial dysfunction accelerates severe iBRB disruption, a process which is increasingly implicated in a cascade of mitochondrial pathologies including mitochondrial DNA destabilization, oxidative stress, calcium homeostasis disruption, mitochondrial autophagy deficiency, and dysregulated dynamic regulation. This review establishes the iBRB as a crossroads for metabolic, redox, and inflammatory signaling. By analyzing evidence from diabetic retinopathy and retinal vein occlusion models, we clarify how mitochondrial decline translates local energy deficiency into chronic barrier dysfunction. We posit that restoring mitochondrial function is indispensable for vascular resilience and regeneration, a conclusion drawn from integrating molecular, cellular, and translational findings. To advance mitochondrial discoveries into clinical practice, subsequent studies must prioritize achieving spatiotemporally controlled, cell-type-specific interventions with robust in vivo efficacy, thereby successfully translating mitochondrial science into clinical vascular medicine.
- 12 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11984
Open AccessWhen Mitochondria Falter, the Barrier Fails: Mechanisms of Inner Blood-Retinal Barrier (iBRB) Injury and Opportunities for Mitochondria-Targeted Repair
As the central hub of retinal metabolism, mitochondria are vital for sustaining the integrity of the inner blood-retinal barrier (iBRB), which is fundamental to retinal homeostasis. Mitochondrial dysfunction accelerates severe iBRB disruption, a process which is increasingly implicated in a cascade of mitochondrial pathologies including mitochondrial DNA destabilization, oxidative stress, calcium homeostasis disruption, mitochondrial autophagy deficiency, and dysregulated dynamic regulation. This review establishes the iBRB as a crossroads for metabolic, redox, and inflammatory signaling. By analyzing evidence from diabetic retinopathy and retinal vein occlusion models, we clarify how mitochondrial decline translates local energy deficiency into chronic barrier dysfunction. We posit that restoring mitochondrial function is indispensable for vascular resilience and regeneration, a conclusion drawn from integrating molecular, cellular, and translational findings. To advance mitochondrial discoveries into clinical practice, subsequent studies must prioritize achieving spatiotemporally controlled, cell-type-specific interventions with robust in vivo efficacy, thereby successfully translating mitochondrial science into clinical vascular medicine.
- Open Access
- 14 May 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 15 (11) , 858-865
Syn3, a newly developed cyclic peptide and BDNF signaling enhancer, ameliorates retinal ganglion cell degeneration in diabetic retinopathy
Dear Editor,
- 14 May 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 15 (11) , 858-865
Open AccessSyn3, a newly developed cyclic peptide and BDNF signaling enhancer, ameliorates retinal ganglion cell degeneration in diabetic retinopathy
Dear Editor,